Guidance Provided for Management of Obesity in Kidney Disease
By Elana Gotkine HealthDay Reporter
MONDAY, Sept. 23, 2024 -- In a report issued by the American Society of Nephrology and published online Sept. 18 in the Journal of the American Society of Nephrology, guidance is presented for the management of obesity in persons with kidney disease.
T. Alp Ikizler, M.D., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues developed kidney health guidance for management of obesity in persons living with kidney disease.
The authors note that weight loss can improve psychosocial functioning, including better mood, heightened quality of life, and slower progression of kidney disease, for patients with obesity and kidney disease. Effective obesity management remains challenging for patients with kidney disease and requires a multidisciplinary team and a combination of multiple interventions. Clinicians should address health-related social needs and identify and treat common mental health comorbidities. Patients should be treated with sensitivity, and clinicians should consider their prior experiences of trauma, racism, discrimination, and weight bias. Lifestyle modification is the first-line therapy for weight loss, and should be implemented regardless of other therapeutic options used. Antiobesity medications may be safe and beneficial for individuals with obesity and kidney diseases, with incretin mimetics representing the most effective and beneficial medications for those with kidney disease. Few trials of metabolic/bariatric surgery have included individuals with kidney disease, but evidence suggests that kidney disease should not be considered a contraindication to these procedures.
"Although the evidence for appropriate management of obesity is expanding in patients living with kidney diseases, gaps in knowledge and implementation require attention," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2024
Read this next
Semaglutide Beneficial for Hidradenitis Suppurativa in Patients With Obesity
WEDNESDAY, Sept. 25, 2024 -- For patients with obesity, the addition of semaglutide to standard hidradenitis suppurativa (HS) treatments yields improvement in quality of life and...
Semaglutide May Lower Risk for Opioid Overdose in T2DM, Opioid Use Disorder
WEDNESDAY, Sept. 25, 2024 -- For patients with type 2 diabetes (T2D) and opioid use disorder (OUD), semaglutide is associated with a significantly lower risk for opioid overdose...
Prevalence of Obesity 40.3 Percent in U.S. From August 2021 to August 2023
TUESDAY, Sept. 24, 2024 -- The prevalence of obesity among adults was 40.3 percent during August 2021 to August 2023, according to a September data brief published by the National...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.